Background {#Sec1}
==========

Hemophagocytic lymphohistiocytosis (HLH) is a very rare life-threatening syndrome characterized by excessive immune activation and hyperinflammation \[[@CR1]\]. HLH can be either familial or secondary to infection, immunosuppression, autoimmune disease, and malignancy \[[@CR2]\]. Acquired HLH is an aggressive clinical entity which require early diagnosis and appropriate therapies. Management of HLH was indicated in the HLH-2004 guidelines, although it was heavily debated \[[@CR3]\]. An especially high incidence of Epstein-Barr virus (EBV)-associated HLH (EBV-HLH) was found in Asia \[[@CR4], [@CR5]\].

Congenital factor VII (FVII) deficiency (OMIM: 227500) is a rare inheritable coagulation disorder with an estimated prevalence of 1:500000, and is inherited in autosomal recessive (AR) model. Clinical manifestations vary from asymptomatic to severe bleeding, and the clinical manifestations do not correlate well with plasma FVII levels, which lead to the patient management during surgery challenging \[[@CR6]\]. Congenital FVII deficiency is characterized by prolonged prothrombin time (PT) and low FVII. 30% was considered as the cutoff for clinical manifestations in patients with FVII deficiency \[[@CR7]\].

We hereby report the first case of patient suffered from both HLH and congenital FVII deficiency.

Case presentation {#Sec2}
=================

HLH {#Sec3}
---

The 50-year-old woman was admitted for a fever persisted for 20 days. Computed tomography (CT) scanning showed pulmonary infection. Cytopenia was observed in peripheral blood. White blood cells, red blood cells, and neutrophil graneulocytes were all decreased. Hemoglobin was only 74.0 g/L. Ferritin was increased to be 3602.5 g/L. Autoimmune antibody test found no abnormity. The available laboratory data were summarized in Table [1](#Tab1){ref-type="table"}.Table 1Laboratory test resultsTestResultReferenceUnitWBC1.24 (↓)3.50--9.5010^9^/LGRA (%)61.340.0--75.0%GRA (\#)0.76 (↓)1.80--6.3010^9^/LLYN (%)37.920.0--50.0%LYN (\#)0.47 (↓)1.10--3.2010^9^/LMONO (%)0.8 (↓)3.0--10.0%MONO (\#)0.01 (↓)0.10--0.6010^9^/LEOS (%)0.0 (↓)0.4--8.0%EOS (\#)0.00 (↓)0.02--0.5210^9^/LBAS (%)0.0 (↓)0--1.0%BAS (\#)0.00 (↓)0.00--0.0610^9^/LRBC2.67 (↓)3.80--5.1010^12^/LHB74.0 (↓)115.0--150.0g/LHCT22.0 (↓)35.0--45.0%MCV82.482.0--100.0fLMCH27.727.0--34.0pgMCHC336316--354g/LPLT146.0125.0--350.010^9^/LPDW10.39.0--17.0fLMPV9.98.0--15.0fLP-LCR23.313.0--43.0%PCT0.140.10--0.25%FER3602.5 (↑)15--150μg/LALT53 (↑)≤33U/LAST60 (↑)≤32U/LLDH737 (↑)135--214U/LALP126 (↑)35--105U/LEBVNegativeNegative--CMVNegativeNegative--*WBC* white blood cell, *GRA* neutrophil graneulocyte, *LYN* lymphocyte, *MONO* Monocyte, *EOS* eosinophil, *BAS* basophil, *RBC* red blood cell, *HB* hemoglobin, *HCT* hematocrit, *MCV* erythrocyte mean corpuscular volume, *MCH* mean corpuscular hemoglobin, *MCHC* mean red blood cell hemoglobin concentration, *PLT* platelet, *PDW* platelet distribution width, *MPV* mean platelet volume, *P-LCR* proportion of large platelet, *PCT* plateletcrit, *FER* ferritin, *ALT* alanine aminotransferase, *AST* aspartate aminotransferase, *LDH* lactate dehydrogenase, *ALP* alkaline phosphatase, *EBV* Epstein-Barr virus, *CMV* Cytomegalovirus

NK cells activity was detected according to IFN-γ secretion by using whole blood as previously established in our laboratory \[[@CR8]\]. Moreover, functional activity of NK cells was detected using K562 cells as target cells. Low activity of NK cells was found in two assays. In both assays, the activity of NK cells was only 30% of the low limit of healthy controls. Bone marrow aspiration confirmed hemophagocytosis (Fig. [1](#Fig1){ref-type="fig"}). Laboratory tests exclude EBV or Cytomegalovirus (CMV) infection, common cause of HLH. This patient was diagnosed and treated according to HLH-2004 guidelines \[[@CR9], [@CR10]\].Fig. 1Bone marrow aspiration. Mononuclear histiocyte with engulfed erythrocyte was observed. G = 64.5%, E = 31.5%, G/E = 2.05:1

To explore the genetic cause of HLH in this patient, a targeted next generation sequencing (NGS) panel was applied, including *LYST, CTPS1, PIK3CD, PRF1, SRGN, CD27, LAMP1, ARF6, GZMB, RAB27A, BLOC1S6, CORO1A, UNC13D, STXBP2, GNLY, STK4, PRKCD, AP3B1, ITK, STX11, CARD11, MCM4, MAGT1, SH2D1A, XIAP,* and *IL2RG* genes. The mean depth was 315 folds. 98.44% of target region was covered by at least 20 folds. The NGS was performed on the Ion Torrent Personal Genome Machine as previously described \[[@CR11]\]. However, NGS targeting HLH associated gene found no pathogenic variant.

Congenital FVII deficiency {#Sec4}
--------------------------

Coagulation tests showed the FVII:C was decreased to be 4%. The FVII:C of the patient's brother was 5%, who suffered postoperative hemorrhage after surgical resection of renal cell carcinoma 3 years ago. Both the patient and her brother showed prolonged PT. Family tree was drawn (Fig. [2a](#Fig2){ref-type="fig"}). Genomic DNA was extracted from peripheral blood mononuclear cell (PBMC). Coding exons and adjacent splice junctions were amplified for the *F7* gene. Sanger sequencing was performed bi-directionally on ABI 3500 Dx. NM_000131.4 was used as reference transcript of the *F7* gene. Genetic analysis of the *F7* gene in the patient and her family members identified recurrent compound heterozygous *F7* c.64 + 5G \> A and c.1224 T \> G (p.His408Gln) mutations in this patient and her brother. Heterozygotes were found in other family members who showed slightly decreased FVII:C (Fig. [2b](#Fig2){ref-type="fig"}, Table [2](#Tab2){ref-type="table"}). Heterozygotes were asymptomatic.Fig. 2Congenital factor VII (FVII) deficiency. **a**, The family tree of a Chinese family with HLH and congenital FVII deficiency. Square and circle denoted male or female respectively. Full-filled square and circle meant patients, and half-filled symbols represented heterozygous carrier. The arrow indicated the proband. A question mark meant that genetic analysis was unavailable. **b**, Sanger sequencing of *F7* c.64 + 5G \> A and c.1224 T \> G mutations. **c**, Splicing site prediction by Splice Site Score Calculation (<http://rulai.cshl.edu/new_alt_exon_db2/HTML/score.html>), Splice Site Prediction by Neural Network (<http://www.fruitfly.org/seq_tools/splice.html>), and Netgene2 (<http://www.cbs.dtu.dk/services/NetGene2/>)Table 2Congenital FVII deficiencyNo.Age (year)F7 c.64 + 5G \> AF7 c.1224 T \> GPTAPTTFVII:CII-163Wild typeHeterozygous14.2--67II-261HeterozygousHeterozygous28.438.95II-450HeterozygousHeterozygous30.334.64III-136HeterozygousWild type14.433.545III-228Wild typeHeterozygous14.537.151

Discussion and conclusions {#Sec5}
==========================

HLH is a severe or fatal inflammatory condition caused by hereditary or acquired immunoregulatory abnormity. Inflammatory cytokine storm caused by the excessive activation and proliferation of macrophages and T-lymphocytes may contribute to HLH pathology \[[@CR12], [@CR13]\]. Primary HLH is an autosomal or X-linked recessive immune disorders. Secondary HLH is often precipitated by infection, autoimmune disease, malignancy, or metabolic conditions, and its prognosis is poor. The initial clinical manifestations of HLH may vary widely and lead to misdiagnosis. For secondary HLH, 8 criteria were proposed (fever, splenomegaly, cytopenia, hypertryglyceridemia or hypofibrinogenemia, high ferritin, elevated soluble CD25, low NK cell activity, and hemophagocytosis in biopsy) and the presence of 5/8 of these criteria confirmed the diagnosis \[[@CR10]\]. Prompt start of therapy was essential and lifesaving. In this study, the patient received anti-infection therapy with Moxifloxacin Hydrochloride for 6 days, and then she was transferred to our department and treated according to HLH-2004 when her fever persisted for 20 days. CT scanning showed pulmonary infection. EBV was not detected, and malignancy could not be excluded.

FVII is involved in the 'initiation' phase via binding tissue factor exposed by cells after endothelial injury. The complex promotes the activation of factor X and IX, leading to the generation of thrombin \[[@CR14]\]. Congenital FVII deficiency is an AR disorder, which is defined by the complete absence or below 70% of normal of FVII \[[@CR15]\]. Clinical manifestations of FVII deficiency were heterogeneous, varying from asymptomatic to fatal bleeding, which do not correlate well with FVII plasma levels. Laboratory test for FVII activity is the first-line method for FVII deficiency diagnosis.

In this family, compound heterozygous *F7* c.64 + 5G \> A and c.1224 T \> G mutations were found in the patient and her brother. Homozygous *F7* c.64 + 5G \> A mutation has been previously reported \[[@CR16]\]. Peyvandi F et al., reported that this mutation might result in the preservation of some FVII coagulant activity and was associated with a mild bleeding history. Three kinds of splicing software were used to predict the effect of *F7* c.64 + 5G \> A mutation on 5′ splicing site (Fig. [2c](#Fig2){ref-type="fig"}). The 5′ splicing site of exon 1 was predicted to be greatly influenced by *F7* c.64 + 5G \> A mutation. *F7* c.1224 T \> G mutation resulted in amino acid substitution of His^408^ to Gln. Katsumi A et al., reported that his mutation leads to impaired secretion of the molecule and FVII deficiency in vitro \[[@CR17]\]. In this family, heterozygotes showed slightly decreased FVII:C, while the patient and her brother showed greatly decreased FVII:C level, both of whom carried compound heterozygous *F7* c.64 + 5G \> A and c.1224 T \> G mutations. These results were consistent with the AR inheritance model.

Bleeding and altered coagulation can occur in patients with HLH, but, vice versa, coagulation defects are associated to more severe HLH \[[@CR18], [@CR19]\]. The most frequently reported hemostasis abnormity is hypofibrinogenemia partially due to fibrinogen consumption by disseminated intravascular coagulation (DIC) \[[@CR1]\]. DIC and thrombocytopenia were associated with adverse outcome in HLH patients \[[@CR20]\]. FVII interacts with tissue factor and activates factor X (FX) binding to platelets, leading to thrombin formation. Thrombin plays a role in the activation of platelets, cleavage of fibrinogen to produce fibrin, and stabilization of clot by the actions of activated factor XIII \[[@CR21]\]. Recombinant factor VIIa (rFVIIa) has been used successfully in HLH patients with severe hemorrhage \[[@CR22], [@CR23]\]. FVII deficiency may increase the bleeding risk of HLH patients.

AR

:   Autosomal recessive

CMV

:   Cytomegalovirus

CT

:   Computed tomography

EBV

:   Epstein-Barr virus

FVII

:   Factor VII

HLH

:   Hemophagocytic lymphohistiocytosis

NGS

:   Next generation sequencing

PBMC

:   Peripheral blood mononuclear cell

PT

:   Prothrombin time

We thank the patients and their family members.

Funding {#FPar1}
=======

This work was partially supported by the National Natural Science Foundation of China (No. 81500925), and Health and Family Planning Commission of Hubei Province 2018 Joint Fund (No. WJ2018H0113).

Availability of data and materials {#FPar2}
==================================

All data generated or analyzed during this study are included in this published article.

WC and YL conceived the experiments. XW performed genetic test and genetic counselling for congenital factor VII deficiency. XW wrote the manuscript. NT performed coagulation tests and NK cell activity assay. DL cared the patient and provided patient samples.

Ethics approval and consent to participate {#FPar3}
==========================================

This study was approved guidelines by the Ethics Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. Written informed consent were obtained from all family members.

Consent for publication {#FPar4}
=======================

Written informed consent for publication of medical data and genetic data were obtained from all family members.

Competing interests {#FPar5}
===================

The authors declare that they have no competing interests.

Publisher's Note {#FPar6}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
